Nanobiotix
Paris
France
206 articles about Nanobiotix
-
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
3/4/2021
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.
-
NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory
3/2/2021
NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory
-
NANOBIOTIX 2020 Q4 and Annual Revenues
2/26/2021
NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced its revenues for the fourth quarter and full year ended December 31, 2020.
-
NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer
1/28/2021
First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer
-
Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021
1/15/2021
Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for patients with rectal cancer show that intratumoral injection of the product candidate was feasible and it was well tolerated at all dose levels
-
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
1/8/2021
Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study
-
Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs
12/18/2020
Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘ Company ’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the closing of an additional 1,095,000 American Depositary Shares (“ ADSs ”) pursuant to the full exercise of the underwriters’ option to purchase additional ADSs in connection with the Company’s initia
-
Biopharma Money on the Move: December 9-15
12/16/2020
A roundup of life sciences companies raking in the cash. -
NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market
12/11/2020
NANOBIOTIX, announced the pricing of its initial public offering on the Nasdaq Global Select Market by way of a capital increase of 7,300,000 new ordinary shares, consisting of a public offering of 5,445,000 ordinary shares in the form of American Depositary Shares, each representing the right to receive one ordinary share, in the United States and a concurrent offering of 1,855,000 ordinary shares in certain jurisdictions outside of the United States to certain investors.
-
IPO Frenzy Continues as 4 More Go Public
12/11/2020
Another four companies join the Nasdaq, bringing the life science IPO count to over 70 this year. -
Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing
12/7/2020
NANOBIOTIX announced the start of its roadshow in connection with its intention to issue and sell, subject to market and other conditions, 6,500,000 ordinary shares of the Company in an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States.
-
Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer
11/17/2020
A phase II study of NBTXR3 activated by radiation and combined with pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma with limited PD-L1 expression or refractory to PD-1 blockade
-
NANOBIOTIX Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3
11/10/2020
Eight of nine patients treated on the study to date showed tumor regression, including six of seven prior anti-PD-1 non-responders
-
NANOBIOTIX Provides Updates on Global Clinical Development Plan for First-in-class Radioenhancer NBTXR3 at ASTRO 2020
10/26/2020
Nanobiotix global development plan for first-in-class radioenhancer NBTXR3 across several solid tumor indications proceeds as planned with focus on priority pathways in head and neck cancer and immunotherapy
-
NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
10/20/2020
NANOBIOTIX, a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced four clinical and/or pre-clinical presentations to be delivered at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.
-
NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA
10/13/2020
First patient injected in phase I trial evaluating NBTXR3 activated by radiation therapy for patients with pancreatic cancer at The University of Texas MD Anderson Cancer Center in clinical collaboration with Nanobiotix
-
NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020
9/4/2020
Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘ Company ’’) , a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its half year financial results for the six-month period ended June 30, 2020. These results are represented in the condensed consolidated financial statements as at 30 June, 2020, reviewed
-
Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020
7/17/2020
Regulatory News: NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘ Company ’’) , a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited revenue for the second quarter of 2020 as well as for the first half of 2020. Revenue for the second quarter of 2020 (unaudited) In K€
-
Nanobiotix Receives Feedback From US FDA to Advance Phase III Head and Neck Cancer Study Design and CMC Development Plan for NDA
6/17/2020
NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’) (Paris:NANO), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the FDA has provided necessary feedback regarding the design of NANORAY-312, the Company’s pivotal phase III global registration trial in head and neck cancer.
-
NANOBIOTIX Spinoff Curadigm Validates Novel Nanoprimer Technology in RNA Therapeutics
6/10/2020
“The data Curadigm will present at AACR provide important validation of the company’s Nanoprimer technology.